Q2 2024 · 13F-HR
Pivotal bioVenture Partners Investment Advisor LLCholdings as filed
Filed 2024-08-13 · accession 0001012975-24-000321
$130.1M
Reported value
10
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 92243G108 | PCVX | VAXCYTE INC | $59.9M | 46.0% | 793,036 | Common | SHARED |
| 45790W108 | — | INOZYME PHARMA INC | $20.0M | 15.4% | 4,494,851 | Common | SHARED |
| H5870P102 | OCS | OCULIS HOLDING AG | $19.1M | 14.7% | 1,595,918 | Common | SHARED |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $19.0M | 14.6% | 2,041,108 | Common | SHARED |
| 30223G102 | EXAIEUR | EXSCIENTIA PLC | $3.9M | 3.02% | 770,500 | Common | SHARED |
| 75120L100 | — | RALLYBIO CORP | $3.2M | 2.48% | 2,404,644 | Common | SHARED |
| 92673K108 | VIGL | VIGIL NEUROSCIENCE INC | $2.2M | 1.72% | 560,595 | Common | SHARED |
| 097702104 | BOLT1EUR | BOLT BIOTHERAPEUTICS INC | $1.4M | 1.09% | 1,891,467 | Common | SHARED |
| 449778109 | IOBTQ | IO BIOTECH INC | $1.0M | 0.78% | 864,197 | Common | SHARED |
| 01626L105 | — | ALIGOS THERAPEUTICS INC | $260,125 | 0.20% | 743,215 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.